Videos

Ankeet Bhatt, MD, MBA, discusses a NUDGE-FLU analysis from ACC.24 examining effect of the CV gain-framed nudge in patients with and without history of AMI.

Ahmad Masri, MD, MS, discusses a study from ACC.24 examining trends in incidence and outcomes of emergency department visits related to hypertrophic cardiomyopathy from 2006 to 2019.

Sara Saberi, MD, discusses 1-year data from a cohort of 46 patients within the FOREST-HCM trial at ACC.24.

Deepak Bhatt, MD, MPH, MBA, provides a recap of top trials and new data from the American College of Cardiology's 2024 Annual Scientific Session.

A trio of experts discuss their perspectives on the recent advancement in pharmacotherapy within the management of hypertrophic cardiomyopathy.

Christie Ballantyne, MD, discusses new data from the ROSE2 trial examining the potential synergistic effects of obicetrapib with ezetimibe in high-intensity statin users.

In the latest Lungcast, Drs. McCurry and Valapour answered several questions on the candidacy of post-infectious COVID-19 patients for lung transplantation and on long COVID.

Martin Maron, MD, discusses the results of the IMPROVE-HCM trial and how it informs the community on the potential of ninerafaxstat.

Christie Ballantyne, MD, discusses data from the SHASTA-2 trial and how it informs the community on the potential of plozasiran in management of severe hypertriglyceridemia.

Veraprapas Kittipibul, MD, discusses an analysis of the TRANSFORM-HF trial at ACC.24.

Muthiah Vaduganathan, MD, MPH, discusses a presentation from ACC.24 assessing the effects of dapagliflozin across a range of left ventricular hypertrophy from DELIVER.

Veraprapas Kittipibul, MD, discusses a study examining costs associated with heart failure hospitalization among patients with HFrEF or HFpEF from within the GWTG-HF registry.

During this segment of Lungcast, Valapour and McCurry discussed recent changes made to lung allocation scores as well as the topic of graft rejection.

Peter A. Campochiaro, MD, discusses the safety and tolerability of RGX-314 gene therapy in treating wet AMD and how these results inform pivotal clinical trials.

This post-AAD interview with Chovatiya covered takeaways regarding recent data on upadacitinib for vitiligo, tapinarof for eczema, and lutikizumab for hidradenitis suppurativa.

In this interview segment, Del Rosso further explores the steps patients and clinicians should take in considering the recent Valisure report on benzene risk for skincare products with benzoyl peroxide.

In this interview, Del Rosso expresses his personal views on the recent report of benzene in benzoyl peroxide acne products.

Deepak Sambhara, MD, discusses how clinical practice has responded to the introduction of aflibercept 8 mg and the significance of extended treatment intervals for patients with retinal diseases.

Michael Weber, MD, lead of the PRECISION trial, discusses the significance of the aprocitentan (Tryvio) approval and key points for providers who may have patients with uncontrolled hypertension.

David M. Brown, MD, discusses the full one-year data from the PULSAR and PHOTON trials and the implications of aflibercept 8 mg for patients with AMD and DME.

In this post-AAD interview, Cohen discusses his contribution to the presentation titled ‘Psoriasis: Modern Therapeutic Approaches.’

Eiran Gorodeski, MD, MPH, Parag Goyal, MD, MSc, and James Fang, MD, discuss the HFSA's recent scientific statement on the prevalence and impact of cognitive impairment on the management of heart failure.

In the final installment in our 5-part video series, our pair of experts in hepatology touch upon how an approval for MASH would impact conversations around screening for asymptomatic patient populations.

In part 4 of our 5-part video series, Arab and Banerjee discuss how the study population of MAESTRO-NASH compares to MASH populations in real-world settings.

In part 3 of our 5-part discussion, Arab and Banerjee dive into the results of the pivotal MAESTRO-NASH trial and how it can inform use of resmetirom in real-world settings.

In part 2 of this 5-part video series, our experts in hepatology discuss the challenges, pitfalls, and recommendations for screening of MASH/MASLD in real-world settings.

In part 1 of this 5-part video series, our experts in hepatology discuss the recent change in nomenclature for NASH/NAFLD as compared to MASH/MASLD and how it effects management.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This edition shares 5 important updates from the American Academy of Dermatology (AAD) 2024 meeting.

James Palmer, MD, provides perspective on the FDA's decision to approve fluticasone propionate nasal spray for adults with chronic rhinosinusitis without nasal polyps.

Data show significant maternal and fetal risks in cases when pregnant women are diagnosed with hidradenitis suppurativa. A researcher discusses opportunities to learn more.